Moser Wealth Advisors LLC Cuts Stock Holdings in Gilead Sciences, Inc. $GILD

Moser Wealth Advisors LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,147 shares of the biopharmaceutical company’s stock after selling 250 shares during the period. Moser Wealth Advisors LLC’s holdings in Gilead Sciences were worth $682,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the first quarter valued at about $25,000. Activest Wealth Management increased its stake in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $27,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Finally, Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GILD. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.61.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. The trade was a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,500 shares of company stock worth $8,281,540 in the last quarter. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Down 0.6%

Shares of NASDAQ GILD opened at $120.74 on Friday. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The firm’s 50 day moving average price is $115.41 and its 200 day moving average price is $110.89. The firm has a market cap of $149.82 billion, a P/E ratio of 24.05, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the business earned $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.